The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
|Videos|September 14, 2019
Dr. Weisel on INSIGHT MM Analysis of Duration of Therapy in Myeloma
Author(s)Katja Weisel, MD
Katja Weisel, MD, myeloma specialist at the University of Tübingen, discusses an analysis of the INSIGHT MM study evaluating fixed-duration versus continuous therapy for patients with multiple myeloma.
Advertisement
Katja Weisel, MD, myeloma specialist at the University of Tübingen, discusses an analysis of the INSIGHT MM study evaluating fixed-duration versus continuous therapy for patients with multiple myeloma.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA approved iberdomide plus daratumumab and dexamethasone for relapsed/refractory multiple myeloma.
Neoadjuvant PD-1–based immunotherapy plus chemotherapy produced pCRs across three cohorts in resectable locally advanced HNSCC.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
Dostarlimab monotherapy produced a 27% response rate in PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
OncLive Weekly News Quiz (8/14/2026): Did You Catch This Week's Myeloma, Lung Cancer, and Polycythemia Vera Updates?
5